Clinical Trial Update: Interleukin-7 and Chemokine (C-C Motif) Ligand 19-expressing CD19-CAR-T for Refractory/Relapsed B Cell Lymphoma. [Phase 2]

View source ↗

Summary

Phase 2 trial investigating IL-7 and CCL19-expressing CD19-CAR-T cells for refractory/relapsed B cell lymphoma; status and results not provided.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Lymphoma

Drugs mentioned

• Interleukin-7 and Chemokine (C-C motif) Ligand 19-expressing CD19-CAR-T

Snippet

Sponsor: Wenbin Qian | Conditions: B Cell Lymphoma | Phase 2 | Status: UNKNOWN